John Dorrance Minna MD

Thoracic Cancer

DIrector, Hamon Center for Therapeutic Oncology Research, Professor, Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Southwestern Medical School

Join to View Full Profile

5323 Harry Hines BlvdDallas, TX 75390
Phone+1 214-645-8600

Summary

Dr. Minna is Director of the Hamon Center for Therapeutic Oncology Research, and Professor of Internal Medicine and Pharmacology at The University of Texas Southwestern Medical Center (1991-present). He holds the Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and the Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research. He graduated from Stanford Medical School (research under Leonard Herzenberg), was a resident at Massachusetts General Hospital, a Research Associate at the NIH (under Dr. Marshal Nirenberg), Chief of the Section of Somatic Cell Genetics, Chief of the NCI-VA and then NCI-Navy Medical Oncology Branches at the National Cancer Institute (1975-1991). His work focuses on understanding the molecular pathogenesis of lung cancer and translating this into the clinic by identifying and targeting acquired lung cancer vulnerabilities. He has trained many investigators in lung cancer research. He has led a joint Lung Cancer NCI Special Program of Research Excellence (SPORE) grant between UTSW and the MD Anderson Cancer Center for 25 years. His publications have an H-Index of 193, and a D-Index of 179 with some 130,000 citations.

Education & Training

National Heart Lung and Blood Institute (NHLBI)Post-Doctoral Fellowship, 1969 - 1973
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1967 - 1969
Stanford University School of MedicineClass of 1967

Certifications & Licensure

CA State Medical License 1972 - Present
TX State Medical License 1992 - 2025
DC State Medical License 1974 - 1997
MD State Medical License 1974 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member American Association of Physicians, 1991
Fellow (FASCO) American Society of Clinical Oncologists, 2007
Elected Member The American Society for Clinical Investigation, 1984

Publications & Presentations

PubMed

High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients.
Ling Cai, Nia G Hammond, Alpaslan Tasdogan, Massar Alsamraae, Chendong Yang
Cancer Discovery. 2025-04-02
Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.
Jui-Chung Chiang, Zengfu Shang, Tracy Rosales, Ling Cai, Wei-Min Chen
Science Advances. 2025-03-14
KSR2 promotes self-renewal and clonogenicity of small-cell lung carcinoma.
Dianna H Huisman, Deepan Chatterjee, Robert A Svoboda, Heidi M Vieira, Abbie S Ireland
Molecular Cancer Research. 2025-03-10

Journal Articles

Retraction Notice to “Sun Exposure Related Methylation in Malignant and Non-Malignant Skin Lesions” [Cancer Letters 245/1-2 (2007) 112-120]
John D Minna, Cancer Letters
Inhibition of thioredoxin/thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis
John V Heymach, Stephen G Swisher, Jack A Roth, John D Minna, Clinical Cancer Research
JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
John D Minna, Jonathan M Kurie, J Jack Lee, Vassiliki A Papadimitrakopoulou, Neda Kalhor, Roy S Herbst, Clinical Cancer Research
Validation of the 12-Gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer
Cesar Moran, Jack A Roth, Yang Xie, John D Minna, Vassiliki A Papadimitrakopoulou, John V Heymach, Stephen G Swisher, Clinical Cancer Research
Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-Proficient Breast Cancers
Yang Xie, John D Minna, Clinical Cancer Research
Join now to see all

Press Mentions

Children’s Research Institute at UT Southwestern Scientists Identify Feature of Aggressive Non-Small Cell Lung CancerFebruary 19th, 2025
Antibody Designed to Fight Immunotherapy-Resistant CancersFebruary 14th, 2025
National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
Join now to see all

Grant Support

Coordinating center for the NCI small cell lung cancer research consortiumSLOAN-KETTERING INST CAN RESEARCH2022–2027
Cancer Center Support Grant (CCSG)National Cancer Institute2021–2026
Vulnerability of SARS-CoV-2 Infection in Lung Cancer Based on Serological Antibody AnalysesNational Cancer Institute2020–2025
Coordinating Center for Small Cell Lung Cancer U01National Cancer Institute2017–2025
Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
Targeting Lung Cancer VulnerabilitiesUT SOUTHWESTERN MEDICAL CENTER1997–2025
The University of Texas SPORE (Special Program of Research Excellence) in Lung Cancer Targeting Lung Cancer VulnerabilitiesNational Cancer Institute1996–2025
Natural Products with Selective Cytoxicity to Non-Small Cell LungNational Cancer Institute2018–2023
Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancerNational Cancer Institute2017–2022
Molecular Pathology Of Lung CancerNational Cancer Institute2005
Characterization Of Human 3P Recessive OncogenesNational Cancer Institute2001–2004
Human 3P Recessive OncogenesNational Cancer Institute1996–1999
Spore In Lung CancerNational Cancer Institute1992–1994